Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pagnesi, M; Kim, WK; Conradi, L; Barbanti, M; Stefanini, GG; Schofer, J; Hildick-Smith, D; Pilgrim, T; Abizaid, A; Zweiker, D; Testa, L; Taramasso, M; Wolf, A; Webb, JG; Sedaghat, A; Van der Heyden, JAS; Ziviello, F; MacCarthy, P; Hamm, CW; Bhadra, OD; Schäfer, U; Costa, G; Tamburino, C; Cannata, F; Reimers, B; Eitan, A; Alsanjari, O; Asami, M; Windecker, S; Siqueira, D; Schmidt, A; Bianchi, G; Bedogni, F; Saccocci, M; Maisano, F; Jensen, CJ; Naber, CK; Alenezi, A; Wood, DA; Sinning, JM; Brouwer, J; Tzalamouras, V; Van Mieghem, NM; Colombo, A; Latib, A.
Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry).
Am J Cardiol. 2020; 125(9):1369-1377
Doi: 10.1016/j.amjcard.2020.02.003
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schmidt Albrecht
- Zweiker David
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Safety and feasibility of transfemoral Acurate neo implantation without systematic predilatation are not fully investigated. Our aim was to evaluate the use and impact of pre-implantation balloon aortic valvuloplasty (pre-BAV) before transcatheter aortic valve implantation (TAVI) with Acurate neo. The NEOPRO Registry retrospectively included 1,263 patients who underwent transfemoral TAVI with Acurate neo at 18 centers between January 2012 and March 2018. Information on pre-BAV was available for 1,262 patients (99.9%). Primary end points were pre-discharge moderate-to-severe paravalvular aortic regurgitation (PAR II+), 30-day new permanent pacemaker implantation, and 30-day all-cause mortality or stroke. A total of 1,262 patients who underwent TAVI with (n = 1,051) or without predilatation (n = 211) were included. A reduction in the pre-BAV rate was observed during the study period (from 95.7% in the first date quintile to 78.4% in the last date quintile). Patients who underwent pre-BAV had higher degrees of aortic valve (AV) and left ventricular outflow tract (LVOT) calcification. Primary endpoints were similar between pre-BAV and no pre-BAV groups (PAR II+ 5.5% vs 3.4%, p = 0.214; 30-day permanent pacemaker implantation 9.0% vs 8.0%, p = 0.660; 30-day death or stroke 4.9% vs 4.4%, p = 0.743). The need for postdilatation and other procedural outcomes were comparable between groups. Predilatation did not have a significant impact on primary endpoints across AV and LVOT calcification subgroups (subgroup analyses) and was not independently associated with primary endpoints (multivariate analyses). In conclusion, transfemoral Acurate neo implantation without predilatation appears to be feasible and safe, especially in patients with milder degrees of AV and LVOT calcification. Copyright © 2020 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Aortic Valve Stenosis - surgery
- Balloon Valvuloplasty - instrumentation
- Dilatation - instrumentation
- Equipment Design -
- Female -
- Humans -
- Male -
- Preoperative Period -
- Registries -
- Retrospective Studies -
- Transcatheter Aortic Valve Replacement - methods